Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TT-00434
i
Other names:
TT-00434
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
TransThera Biosci
Drug class:
FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor
Related drugs:
‹
erdafitinib (70)
surufatinib (7)
Max-40279 (2)
amlexanox (1)
HMPL-453 (1)
BMS-582664 (1)
ASP5878 (0)
FP-1039 (0)
HH185 (0)
LY2874455 (0)
OM-RCA-01 (0)
R1530 (0)
S-49076 (0)
SKI-G-801 (0)
RLY-4008 (3)
ABSK061 (0)
CGT4859 (0)
DS-1123 (0)
RPT835 (0)
PBI-05204 (0)
B-701 (2)
TYRA-300 (1)
FPI-1966 (0)
LY3866288 (0)
R3Mab (0)
erdafitinib (70)
surufatinib (7)
Max-40279 (2)
amlexanox (1)
HMPL-453 (1)
BMS-582664 (1)
ASP5878 (0)
FP-1039 (0)
HH185 (0)
LY2874455 (0)
OM-RCA-01 (0)
R1530 (0)
S-49076 (0)
SKI-G-801 (0)
RLY-4008 (3)
ABSK061 (0)
CGT4859 (0)
DS-1123 (0)
RPT835 (0)
PBI-05204 (0)
B-701 (2)
TYRA-300 (1)
FPI-1966 (0)
LY3866288 (0)
R3Mab (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2-ARHGAP24 fusion
Cholangiocarcinoma
FGFR2-ARHGAP24 fusion
Cholangiocarcinoma
TT-00434
Sensitive: C3 – Early Trials
TT-00434
Sensitive
:
C3
TT-00434
Sensitive: C3 – Early Trials
TT-00434
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login